Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

Por Attard, Gerhardt, Reid, Alison H.M., A’Hern, Roger, Parker, Christopher, Oommen, Nikhil Babu, Folkerd, Elizabeth, Messiou, Christina, Molife, L. Rhoda, Maier, Gal, Thompson, Emilda, Olmos, David, Sinha, Rajesh, Lee, Gloria, Dowsett, Mitch, Kaye, Stan B., Dearnaley, David, Kheoh, Thian, Molina, Arturo, de Bono, Johann S.
Publicado em 2009

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

Por Olmos, David, Brewer, Daniel, Clark, Jeremy, Danila, Daniel C, Parker, Chris, Attard, Gerhardt, Fleisher, Martin, Reid, Alison H M, Castro, Elena, Sandhu, Shahneen K, Barwell, Lorraine, Oommen, Nikhil Babu, Carreira, Suzanne, Drake, Charles G, Jones, Robert, Cooper, Colin S, Scher, Howard I, de Bono, Johann S
Publicado no Lancet Oncol (2012)

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

Por Reid, Alison H.M., Attard, Gerhardt, Danila, Daniel C., Oommen, Nikhil Babu, Olmos, David, Fong, Peter C., Molife, L. Rhoda, Hunt, Joanne, Messiou, Christina, Parker, Christopher, Dearnaley, David, Swennenhuis, Joost F., Terstappen, Leon W.M.M., Lee, Gloria, Kheoh, Thian, Molina, Arturo, Ryan, Charles J., Small, Eric, Scher, Howard I., de Bono, Johann S.
Publicado em 2010